AI assistant
IMMUTEP LIMITED — Board/Management Information 2007
Dec 19, 2007
65122_rns_2007-12-19_cb063ba6-a15e-47d4-9a74-f9c28d4ad7b8.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [193 x 52] intentionally omitted <==
COMPANY ANNOUNCEMENT
Board and Principal Place of Business Changes
Thursday 20[th] December 2007, Melbourne, Australia: Prima Biomed Limited (ASX: PRR) today announced the appointment of Mr Ata Gokyildirim as Non-executive Chairman of the Board. Mr Gokyildirim has extensive merchant banking experience and recently Mr Gokyildirim founded a marketing and distribution business for the pharmaceutical industry in Turkey and the Middle East. He has recently joined Super Structure Services as an executive to help restructure companies in need and deliver substantial shareholder returns from these reforms.
Mr Eugene Kopp has resigned from his position as an Executive Chairman and Director of the Company to pursue interests outside of the biotechnology sector. Mr Kopp has been an Executive Chairman of Prima BioMed’s since November 2004 and has led the company through a number of technical milestones, including the successful conclusion of the CancerVac Ovarian Cancer Phase IIa. Mr Kopp will continue to work with the Prima team, in a consulting role for an initial period of 7 months to assist in the transition of the technology portfolio.
The Board would like to thank Mr Kopp for his significant contribution to Prima BioMed.
The Company also wishes to announce that it has moved to a new Principal Place of Business located at: Suite 1705, 109 Pitt Street
Sydney, NSW, 2000
Phone +61 (0) 2 9232 4420 Fax +61 (0) 2 9232 4450
For further information:
Company Enquiries Phillip Hains
03 9824 5254
About Prima Biomed Ltd
Prima Biomed (ASX: PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima’s lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer.
For further information, visit www.primabiomed.com.au
Prima BioMed Ltd , - Registered Office: Suite 1, 1233 High St, Armadale VIC 3143 AUSTRALIA Ph: +61 (0)3 9854 5700 Fax: +61 (0)3 9822 7735 www.primabiomed.com.au